Login to Your Account

Arakis' £28M Third Round Enough To Last Until 2007

By Nuala Moran

Wednesday, September 8, 2004
LONDON - Arakis Ltd. raised £29 million (US$52 million) in its third funding round, providing enough money to take the company to 2007 and allowing it to start U.S. and European Phase III trials of AD 923 in cancer breakthrough pain. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription